This week, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced the FDA’s August 16 decision to designate MDMA as a breakthrough therapy. Along with this designation, the FDA has approved Phase 3 trials to test the effectiveness of the drug in treating PTSD. According to a press release from MAPS, which has lobbied for the
FDA Labels MDMA As ‘Breakthrough Therapy’ For PTSD
According to a press release from MAPS, which has long lobbied for the medicinal use of MDMA, the “breakthrough” status may lead to quicker approval for the substance.
By Carey Wedler
